{"title":"补充螺旋藻（Arthrospira platensis）对便秘为主的肠易激综合征患者肠道通透性、抗氧化和炎症标志物、生活质量和疾病严重程度的影响：一项随机双盲、安慰剂对照试验","authors":"Saeede Jafari Nasab, Awat Feizi, Parisa Hajihashemi, Mohammad-Hassan Entezari, Manoj Sharma, Peyman Adibi, Mohammad Bagherniya","doi":"10.1186/s12937-025-01132-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder (FGID) which is characterized by chronic pain related to defecation and alteration in GI motility. Recent findings indicated that intestinal barrier dysfunction, hyperpermeability, oxidative stress, and inflammation play a role in IBS pathogenesis. Considering the antioxidant properties of Spirulina (Arthrospira) platensis (SP), this study aimed to investigate the effect of SP supplementation on Quality of life (QoL), disease severity, antioxidant capacity, oxidative stress index and intestinal permeability in constipation-dominant IBS (IBS-C) patients.</p><p><strong>Methods: </strong>This study was a parallel randomized, double-blind, placebo-controlled clinical trial involving 60 IBS-C patients aged 18-50 years. The patients were given either 1 g SP (two capsules/day; each capsule contained 500 mg of SP) or placebo for 12 weeks. IBS-QoL, IBS-Severity system score (IBS-SSS), plasma total antioxidant capacity (TAC), malondialdehyde (MDA), and zonulin levels were measured at baseline and the end of the intervention. Univariate comparison and intention-to-treat (ITT) were used for analysis.</p><p><strong>Results: </strong>SP supplementation compared to placebo resulted in a significant increase in QoL score (7.05 ± 2.02 vs. - 1.57 ± 2.49; p = 0.008), TAC (145.27 ± 30.77 vs. -54.90 ± 45.72; p < 0.001) and decrease in IBS-SSS (-32.17 ± 8.96 vs. 1.07 ± 8.49; p = 0.002), MDA level (- 11.61 ± 2.57 vs. - 2.00 ± 2.24; p < 0.001) and zonulin level (- 0.22 ± 0.05 vs. 0.12 ± 0.07; p = 0.001). These results remained significant after adjusting for baseline values.</p><p><strong>Conclusions: </strong>SP supplementation demonstrated a promising effect in the management of IBS. However, larger trials with a dose-dependent approach in IBS-C and other subtypes of IBS are warranted.</p><p><strong>Trial registration: </strong>The study protocol was approved by the ethical committee at the Isfahan University of Medical Sciences (Registration No. IR.MUI.</p><p><strong>Research: </strong>REC.1401.370) and registered online at http://www.IRCT.ir (code: IRCT20140208016529N8, approved date 25.04.2023).</p>","PeriodicalId":19203,"journal":{"name":"Nutrition Journal","volume":"24 1","pages":"64"},"PeriodicalIF":4.4000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013150/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Spirulina (Arthrospira) platensis supplementation on intestinal permeability, antioxidant and inflammatory markers, quality of life and disease severity in patients with constipated-predominant irritable bowel syndrome: a randomized double‑blind, placebo‑controlled trial.\",\"authors\":\"Saeede Jafari Nasab, Awat Feizi, Parisa Hajihashemi, Mohammad-Hassan Entezari, Manoj Sharma, Peyman Adibi, Mohammad Bagherniya\",\"doi\":\"10.1186/s12937-025-01132-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder (FGID) which is characterized by chronic pain related to defecation and alteration in GI motility. Recent findings indicated that intestinal barrier dysfunction, hyperpermeability, oxidative stress, and inflammation play a role in IBS pathogenesis. Considering the antioxidant properties of Spirulina (Arthrospira) platensis (SP), this study aimed to investigate the effect of SP supplementation on Quality of life (QoL), disease severity, antioxidant capacity, oxidative stress index and intestinal permeability in constipation-dominant IBS (IBS-C) patients.</p><p><strong>Methods: </strong>This study was a parallel randomized, double-blind, placebo-controlled clinical trial involving 60 IBS-C patients aged 18-50 years. The patients were given either 1 g SP (two capsules/day; each capsule contained 500 mg of SP) or placebo for 12 weeks. IBS-QoL, IBS-Severity system score (IBS-SSS), plasma total antioxidant capacity (TAC), malondialdehyde (MDA), and zonulin levels were measured at baseline and the end of the intervention. Univariate comparison and intention-to-treat (ITT) were used for analysis.</p><p><strong>Results: </strong>SP supplementation compared to placebo resulted in a significant increase in QoL score (7.05 ± 2.02 vs. - 1.57 ± 2.49; p = 0.008), TAC (145.27 ± 30.77 vs. -54.90 ± 45.72; p < 0.001) and decrease in IBS-SSS (-32.17 ± 8.96 vs. 1.07 ± 8.49; p = 0.002), MDA level (- 11.61 ± 2.57 vs. - 2.00 ± 2.24; p < 0.001) and zonulin level (- 0.22 ± 0.05 vs. 0.12 ± 0.07; p = 0.001). These results remained significant after adjusting for baseline values.</p><p><strong>Conclusions: </strong>SP supplementation demonstrated a promising effect in the management of IBS. However, larger trials with a dose-dependent approach in IBS-C and other subtypes of IBS are warranted.</p><p><strong>Trial registration: </strong>The study protocol was approved by the ethical committee at the Isfahan University of Medical Sciences (Registration No. IR.MUI.</p><p><strong>Research: </strong>REC.1401.370) and registered online at http://www.IRCT.ir (code: IRCT20140208016529N8, approved date 25.04.2023).</p>\",\"PeriodicalId\":19203,\"journal\":{\"name\":\"Nutrition Journal\",\"volume\":\"24 1\",\"pages\":\"64\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013150/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nutrition Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12937-025-01132-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12937-025-01132-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
摘要
背景：肠易激综合征（IBS）是一种慢性功能性胃肠道疾病（FGID），其特征是与排便和胃肠道运动改变有关的慢性疼痛。最近的研究表明，肠屏障功能障碍、高通透性、氧化应激和炎症在IBS发病中起作用。考虑到螺旋藻（Arthrospira） platensis （SP）的抗氧化特性，本研究旨在探讨补充SP对便秘型IBS （IBS- c）患者生活质量（QoL）、疾病严重程度、抗氧化能力、氧化应激指数和肠道通透性的影响。方法：本研究是一项平行、随机、双盲、安慰剂对照的临床试验，涉及60例18-50岁的IBS-C患者。患者分别给予1 g SP(2粒/天；每个胶囊含有500毫克SP)或安慰剂，持续12周。在基线和干预结束时测量IBS-QoL、ibs -严重性系统评分（IBS-SSS）、血浆总抗氧化能力（TAC）、丙二醛（MDA）和zonulin水平。采用单变量比较和意向治疗（ITT）进行分析。结果：与安慰剂相比，补充SP可显著提高患者的生活质量评分(7.05±2.02 vs - 1.57±2.49；p = 0.008), TAC(145.27±30.77和-54.90±45.72;结论：补充SP对IBS的治疗有很好的效果。然而，在IBS- c和其他IBS亚型中采用剂量依赖方法的更大规模试验是有必要的。试验注册：研究方案已获得伊斯法罕医科大学伦理委员会的批准(注册号：IR.MUI.Research: REC.1401.370)，网上注册：http://www.IRCT.ir（代码：IRCT20140208016529N8，批准日期：2023年4月25日）。
Effects of Spirulina (Arthrospira) platensis supplementation on intestinal permeability, antioxidant and inflammatory markers, quality of life and disease severity in patients with constipated-predominant irritable bowel syndrome: a randomized double‑blind, placebo‑controlled trial.
Background: Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder (FGID) which is characterized by chronic pain related to defecation and alteration in GI motility. Recent findings indicated that intestinal barrier dysfunction, hyperpermeability, oxidative stress, and inflammation play a role in IBS pathogenesis. Considering the antioxidant properties of Spirulina (Arthrospira) platensis (SP), this study aimed to investigate the effect of SP supplementation on Quality of life (QoL), disease severity, antioxidant capacity, oxidative stress index and intestinal permeability in constipation-dominant IBS (IBS-C) patients.
Methods: This study was a parallel randomized, double-blind, placebo-controlled clinical trial involving 60 IBS-C patients aged 18-50 years. The patients were given either 1 g SP (two capsules/day; each capsule contained 500 mg of SP) or placebo for 12 weeks. IBS-QoL, IBS-Severity system score (IBS-SSS), plasma total antioxidant capacity (TAC), malondialdehyde (MDA), and zonulin levels were measured at baseline and the end of the intervention. Univariate comparison and intention-to-treat (ITT) were used for analysis.
Results: SP supplementation compared to placebo resulted in a significant increase in QoL score (7.05 ± 2.02 vs. - 1.57 ± 2.49; p = 0.008), TAC (145.27 ± 30.77 vs. -54.90 ± 45.72; p < 0.001) and decrease in IBS-SSS (-32.17 ± 8.96 vs. 1.07 ± 8.49; p = 0.002), MDA level (- 11.61 ± 2.57 vs. - 2.00 ± 2.24; p < 0.001) and zonulin level (- 0.22 ± 0.05 vs. 0.12 ± 0.07; p = 0.001). These results remained significant after adjusting for baseline values.
Conclusions: SP supplementation demonstrated a promising effect in the management of IBS. However, larger trials with a dose-dependent approach in IBS-C and other subtypes of IBS are warranted.
Trial registration: The study protocol was approved by the ethical committee at the Isfahan University of Medical Sciences (Registration No. IR.MUI.
Research: REC.1401.370) and registered online at http://www.IRCT.ir (code: IRCT20140208016529N8, approved date 25.04.2023).
期刊介绍：
Nutrition Journal publishes surveillance, epidemiologic, and intervention research that sheds light on i) influences (e.g., familial, environmental) on eating patterns; ii) associations between eating patterns and health, and iii) strategies to improve eating patterns among populations. The journal also welcomes manuscripts reporting on the psychometric properties (e.g., validity, reliability) and feasibility of methods (e.g., for assessing dietary intake) for human nutrition research. In addition, study protocols for controlled trials and cohort studies, with an emphasis on methods for assessing dietary exposures and outcomes as well as intervention components, will be considered.
Manuscripts that consider eating patterns holistically, as opposed to solely reductionist approaches that focus on specific dietary components in isolation, are encouraged. Also encouraged are papers that take a holistic or systems perspective in attempting to understand possible compensatory and differential effects of nutrition interventions. The journal does not consider animal studies.
In addition to the influence of eating patterns for human health, we also invite research providing insights into the environmental sustainability of dietary practices. Again, a holistic perspective is encouraged, for example, through the consideration of how eating patterns might maximize both human and planetary health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
